[go: up one dir, main page]

WO2001041750A3 - Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics - Google Patents

Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics Download PDF

Info

Publication number
WO2001041750A3
WO2001041750A3 PCT/US2000/033060 US0033060W WO0141750A3 WO 2001041750 A3 WO2001041750 A3 WO 2001041750A3 US 0033060 W US0033060 W US 0033060W WO 0141750 A3 WO0141750 A3 WO 0141750A3
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
dioxino
neuroleptics
benzylamino
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/033060
Other languages
French (fr)
Other versions
WO2001041750A2 (en
Inventor
Karen Lovell Marquis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200200656A priority Critical patent/EA005002B1/en
Priority to HU0203309A priority patent/HUP0203309A3/en
Priority to MXPA02005649A priority patent/MXPA02005649A/en
Priority to EP00982461A priority patent/EP1235570A2/en
Priority to NZ519381A priority patent/NZ519381A/en
Priority to JP2001543095A priority patent/JP5557409B2/en
Priority to KR1020027007286A priority patent/KR100772854B1/en
Priority to HK02107378.5A priority patent/HK1045942A1/en
Priority to BR0016168-3A priority patent/BR0016168A/en
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to IL14966900A priority patent/IL149669A0/en
Priority to AU19490/01A priority patent/AU784211B2/en
Priority to CA002396351A priority patent/CA2396351C/en
Publication of WO2001041750A2 publication Critical patent/WO2001041750A2/en
Publication of WO2001041750A3 publication Critical patent/WO2001041750A3/en
Priority to IL149669A priority patent/IL149669A/en
Priority to NO20022739A priority patent/NO20022739D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Therapeutic combinations useful in the treatment or prevention of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of prevention disorders are provided.
PCT/US2000/033060 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics Ceased WO2001041750A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR0016168-3A BR0016168A (en) 1999-12-10 2000-12-07 Therapeutic combinations of (s) -2- (benzylaminomethyl) -2,3,8,9tetrahydro-7h-1,4-dioxy in [2,3 -e] indol-8-one and neuroleptics for the treatment or prevention of disorders psychotic
MXPA02005649A MXPA02005649A (en) 1999-12-10 2000-12-07 Combinations of (s)-2 -(benzylamino -methyl)-2, 3, 8, 9, -tetrahydro-7h -1, 4-dioxino(2, 3)-e indol -8-one and neuroleptics.
IL14966900A IL149669A0 (en) 1999-12-10 2000-12-07 NEW THERAPEUTIC COMBINATIONS OF (S) -2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e] INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
NZ519381A NZ519381A (en) 1999-12-10 2000-12-07 New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
JP2001543095A JP5557409B2 (en) 1999-12-10 2000-12-07 Combination of (S) -2- (benzylaminomethyl) -2,3,8,9-tetrahydro-7H-1,4-dioxino (2,3) Eindol-8-one with a neuroleptic
KR1020027007286A KR100772854B1 (en) 1999-12-10 2000-12-07 Of (S) -2- (benzylamino-methyl) -2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-ｅ] indole-8-one and antipsychotic agents Formulation
HK02107378.5A HK1045942A1 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
EA200200656A EA005002B1 (en) 1999-12-10 2000-12-07 NOVEL THERAPEUTIC COMBINATIONS OF (S)-2(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO(2,3-e)-INDOL-8-ONE AND NEUROLEPTICS FOR TREATING OR PREVENTION OF PSYCHOTIC DISORDERS
EP00982461A EP1235570A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
HU0203309A HUP0203309A3 (en) 1999-12-10 2000-12-07 Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
AU19490/01A AU784211B2 (en) 1999-12-10 2000-12-07 Combinations of (S)-2(benzylamino-methyl)-2,3,8,9,- tetrahydro-7H-1,4-dioxino(2,3)-E indol-8-one and neuroleptics
CA002396351A CA2396351C (en) 1999-12-10 2000-12-07 New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
IL149669A IL149669A (en) 1999-12-10 2002-05-15 THERAPEUTIC COMBINATIONS OF (S)-2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
NO20022739A NO20022739D0 (en) 1999-12-10 2002-06-07 New therapeutic combinations of (S) -2- (benzylamino-methyl) - 2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one and neuroleptics for treatment or prevention of psychotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10

Publications (2)

Publication Number Publication Date
WO2001041750A2 WO2001041750A2 (en) 2001-06-14
WO2001041750A3 true WO2001041750A3 (en) 2002-02-14

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033060 Ceased WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Country Status (20)

Country Link
EP (1) EP1235570A2 (en)
JP (1) JP5557409B2 (en)
KR (1) KR100772854B1 (en)
CN (1) CN1230164C (en)
AR (1) AR026756A1 (en)
AU (1) AU784211B2 (en)
BR (1) BR0016168A (en)
CA (1) CA2396351C (en)
CZ (1) CZ20021880A3 (en)
EA (1) EA005002B1 (en)
HK (1) HK1045942A1 (en)
HU (1) HUP0203309A3 (en)
IL (2) IL149669A0 (en)
MX (1) MXPA02005649A (en)
NO (1) NO20022739D0 (en)
NZ (1) NZ519381A (en)
PL (1) PL355292A1 (en)
TW (1) TWI222864B (en)
WO (1) WO2001041750A2 (en)
ZA (1) ZA200205484B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874767A (en) 2003-10-29 2006-12-06 惠氏公司 Sustained-release pharmaceutical composition comprising APLINDORE and its derivatives
TW200640931A (en) 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
RU2481123C2 (en) * 2008-02-13 2013-05-10 Таргасепт, Инк. Combination of alpha 7 nicotinic receptor agonists and antipsychotic agents
PT3906927T (en) * 2020-05-04 2022-07-27 Bioprojet Pharma Use of dopamine d3 partial agonists for treating central nervous system disorders
GB202014184D0 (en) 2020-09-09 2020-10-21 Johnson Matthey Plc Modifed catalyst supports and catalysts supported thereon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771800A2 (en) * 1995-11-06 1997-05-07 American Home Products Corporation Dioxino derivatives and their use as dopamine agonists
WO1998029415A1 (en) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (en) * 1995-03-16 1999-12-06 大塚製薬 株式会社 Method for producing carbostyril derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771800A2 (en) * 1995-11-06 1997-05-07 American Home Products Corporation Dioxino derivatives and their use as dopamine agonists
US5962465A (en) * 1995-11-06 1999-10-05 American Home Products Corporation Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino- 2,3-e!-indol-8-ones and derivatives
WO1998029415A1 (en) * 1996-12-27 1998-07-09 Knoll Aktiengesellschaft Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP5557409B2 (en) 2014-07-23
CN1230164C (en) 2005-12-07
EP1235570A2 (en) 2002-09-04
NZ519381A (en) 2004-04-30
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
HUP0203309A2 (en) 2003-01-28
WO2001041750A2 (en) 2001-06-14
TWI222864B (en) 2004-11-01
AR026756A1 (en) 2003-02-26
IL149669A0 (en) 2002-11-10
KR20030016207A (en) 2003-02-26
EA200200656A1 (en) 2002-12-26
CN1409633A (en) 2003-04-09
BR0016168A (en) 2002-08-20
CZ20021880A3 (en) 2002-08-14
KR100772854B1 (en) 2007-11-02
HUP0203309A3 (en) 2004-12-28
JP2003516350A (en) 2003-05-13
ZA200205484B (en) 2003-12-31
MXPA02005649A (en) 2004-09-10
AU1949001A (en) 2001-06-18
CA2396351A1 (en) 2001-06-14
NO20022739L (en) 2002-06-07
HK1045942A1 (en) 2002-12-20
IL149669A (en) 2006-06-11
NO20022739D0 (en) 2002-06-07
EA005002B1 (en) 2004-10-28
PL355292A1 (en) 2004-04-05

Similar Documents

Publication Publication Date Title
HK1041637A1 (en) Valdecoxib compositions
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
CA2402652A1 (en) Viscoelastics for use in middle ear surgery
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2002247876A1 (en) Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2002363411A1 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO2001041750A3 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
WO2000061231A3 (en) Medical use
WO1999051617A3 (en) FORM VI 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
AU2092300A (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
WO2004006887A3 (en) Composition and methods for the treatment of skin disorders
BG104914A (en) Paroxetine maleate
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
WO2000063348A3 (en) Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof
AU3061199A (en) Skin treatment compositions and the use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149669

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 543095

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2396351

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000982461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-1880

Country of ref document: CZ

Ref document number: 19490/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519381

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027007286

Country of ref document: KR

Ref document number: PA/a/2002/005649

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008169527

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200200656

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: PV2002-1880

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000982461

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027007286

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 519381

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519381

Country of ref document: NZ